Related Experiment Videos
1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists
Robert Epple1, Mihai Azimioara, Ross Russo
1Department of Medicinal Chemistry, The Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA. repple@gnf.org
Bioorganic & Medicinal Chemistry Letters
|March 21, 2006
Summary
Researchers developed potent and selective PPARdelta agonists, inspired by GW2433. Compound 1 is a bioavailable tool for studying selective PPARdelta activation effects.
Area of Science:
- Medicinal Chemistry
- Molecular Pharmacology
- Drug Discovery
Background:
- Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in metabolic regulation.
- PPARdelta (PPARδ) agonists have therapeutic potential but require selective compounds to avoid off-target effects.
Purpose of the Study:
- To design and synthesize novel, highly potent, and selective PPARdelta agonists.
- To evaluate the pharmacological profile of newly synthesized compounds, including bioavailability and subtype selectivity.
Main Methods:
- Structure-based drug design utilizing GW2433 as a template.
- Synthesis of a series of PPARdelta agonist candidates.
- In vitro assays to determine potency (IC50) and selectivity against PPAR subtypes (alpha, gamma).
- Assessment of oral bioavailability in preclinical models.
Main Results:
- A series of potent and selective PPARdelta agonists were identified.
- Compound 1 demonstrated high potency (10 nM) and excellent selectivity, with no cross-activity against other PPAR subtypes up to 10 microM.
- Compound 1 exhibited favorable bioavailability characteristics.
Conclusions:
- Compound 1 represents a valuable pharmacological tool for investigating the biological roles of selective PPARdelta activation.
- The developed agonists offer potential for further therapeutic development targeting metabolic diseases.